Skip to content

LBRX LBRX Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$95K-75.8%

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: LBRX’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's payments of stock issuance costs?
LBRX (LBRX) reported payments of stock issuance costs of $1.17M in Q4 2025.
What does payments of stock issuance costs mean?
Captures the direct costs incurred in connection with the issuance of equity, such as underwriting fees, legal expenses, and registration costs. Monitoring these costs helps assess the efficiency of the company's capital raising activities and the impact of transaction friction on net proceeds.